TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01126645

Intervention type: PROCEDURE
Group type: OTHER
Intervention: RFA
Description: A max.of 2 percutaneous RFA sessions is permitted per patient with a max.of 2 liver lesions treated in each RFA session. Randomization to sorafenib or placebo is performed after completion of RFA. Percutaneous RFA is to be performed according to the manufacturer's instructions and following as far as possible routine procedures of the participating hospital. Typically, RFA will be performed under conscious sedation, general anesthesia is permitted. After local anesthesia of the site of puncture, the applicator is positioned in the center of the lesion using ultrasound-, CT- or MR-guidance. The success of ablation is to be controlled directly after RFA using ultrasound, contrast-enhanced CT, or MR imaging. If for any reason RFA is deemed incomplete within the immediate follow-up (up to 2 weeks after the initial ablation), RFA is to be repeated once (in this case, the total (max.) number of RFA sessions will be three).~The study procedure guide will contain further instructions for RFA.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Radioembolization (SIRT)
Description: One SIRT prescription consists of the pre-treatment assessment followed by one or 2 treatment sessions The aim of pre-treatment assessment is to ensure delivery of the microspheres to the target. Evaluation includes a determination of the arterial location and any consequent necessity for coil-embolization of the gastroduodenal artery, right gastric artery and any other accessory arteries to prevent inadvertent administration of microspheres into the gastrointestinal tract or pancreas. In addition, parasitic extrahepatic supply should be coil-embolized.~Patients in whom the shunt fraction indicates potential exposure to the lung to an absorbed radiation dose of more than 30 Gy should be excluded from treatment with SIR-Spheres. Patients who are randomized to receive SIRT but who are not regarded as eligible for SIRT after the pre-treatment assessment will be switched to the sorafenib only group within the palliative treatment arm.
Study: NCT01100606

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EUR-1008 (APT-1008)
Description: EUR-1008 (APT-1008) (Zenpep® \[pancrelipase\] delayed release capsule) from open capsule, mixed with a small amount of apple juice, will be given orally daily using a syringe nurser at dose increments of 3,000 lipase units, for 10 days in either first treatment period or second treatment period. Total dose will not exceed 10,000 lipase units per kilogram (kg) of body weight per day.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EUR-1008 (APT-1008)
Description: EUR-1008 (APT-1008) (Zenpep® \[pancrelipase\] delayed release capsule) from open capsule, mixed with a small amount of apple sauce, will be given orally daily using a spoon at dose increments of 3,000 lipase units, for 10 days in either first treatment period or second treatment period. Total dose will not exceed 10,000 lipase units per kg of body weight per day.
Study: NCT04440020

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Beverage of Olive Oil Leaves
Description: Beverage of Olive Oil Leaves,Oleuropein

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Mediterranean Diet
Description: Mediterranean Diet ,for a personal nutrition with the same dietary habits
Study: NCT01762904

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Bacterial culture of the prepared skin's areas with two antiseptics and two controls
Description: Cultures will be taken with a scrub-cup of 5 cm2 of internal area pressed over the skin previously prepared with the substances, then it added a 3 mL of culture broth (D/E Neutralizing Broth, Difco TM) containing a neutralizing agent as washing solution. The skin will scrub with a sterile rubber policeman for 1 minute and the procedure will be conducted once again. Both aliquots will gather together in a sterile tube, and a sample of 50 microliters will spread in a plate containing a neutralizing agar (D/E neutralizing Agar, Difco TM) and incubate at 35°C for 24 hrs. After incubation, the colonies will be counted.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Preparing skin's areas to be tested with two antiseptics and two controls
Description: All volunteers will be provided with a neutral soap and shampoo without antiseptics for use during a period of two weeks (phase of stabilization of the skin flora). Two antiseptics (2% chlorhexidine gluconate in 70% isopropyl alcohol and 1% triclosan in 70% isopropyl alcohol) and two controls (Scrub the skin without prior application of any substance and Deionized water redistilled) will be tested as skin antiseptics. The intervention consists of preparing four skin's areas with antiseptics and controls, two in each arm of the volunteer. These ones were approximately 25 cm2 on the forearm for each antiseptic or control. The substances will be applied in an outward circular motion using a sterile swab soaked with the solutions. The solution will remain on the skin for 60 seconds, 3 hours and 24 hours before the bacterial culture will be conducted. For the control where it will be does not apply any substance, the scrub starts immediately.
Study: NCT01294397

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etanercept
Description: Administered by subcutaneous injection once a week

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Denosumab
Description: Administered by subcutaneous injection
Study: NCT01541852

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Losmapimod
Description: One tablet of Losmapimod 7.5mg twice daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: One tablet twice daily
Study: NCT03414021

Intervention type: DIAGNOSTIC_TEST
Intervention: SPECT-CT Scan
Description: Injection of a Tracer and SPECT-CT Scan

Intervention type: DIAGNOSTIC_TEST
Intervention: SPECT-CT Scan
Description: Injection of a Tracer and SPECT-CT Scan

Intervention type: DIAGNOSTIC_TEST
Intervention: SPECT-CT Scan
Description: Injection of a Tracer and SPECT-CT Scan

Intervention type: DIAGNOSTIC_TEST
Intervention: SPECT-CT Scan
Description: Injection of a Tracer and SPECT-CT Scan

Intervention type: DIAGNOSTIC_TEST
Intervention: SPECT-CT Scan
Description: Injection of a Tracer and SPECT-CT Scan
Study: NCT02474719

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: comparison of two regimens in peritoneal dialysis
Description: Dialysate samples (8 by scheme, volume of 10 mL) are collected at each cycle (one at the beginning and one at the end of the cycle). A blood sample (5 mL) is collected at the beginning of the second scheme and a 24-hour urine sample at the end of the second scheme.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: comparison of two regimens in peritoneal dialysis
Description: Dialysate samples (8 by scheme, volume of 10 mL) are collected at each cycle (one at the beginning and one at the end of the cycle). A blood sample (5 mL) is collected at the beginning of the second scheme and a 24-hour urine sample at the end of the second scheme.
Study: NCT02345590

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eplerenone
Description: 25mg of eplerenone

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Eplerenone
Description: 25mg of eplerenone
Study: NCT00354757

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: rabeprazole

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: rabeprazole
Study: NCT03424070

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Shoulder Roll
Description: The POGO score assesses the percent of the glottic opening that can be seen with and without the shoulder roll.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: No shoulder roll (placebo)
Description: Placebo
Study: NCT03638076

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GLS4
Description: Subject in group A will receive Mesilate Capsule 120mg twice daily. Subject in group B will receive Mesilate Capsule 120mg three times daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GLS4
Description: Subject in group A will receive Mesilate Capsule 120mg twice daily. Subject in group B will receive Mesilate Capsule 120mg three times daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RTV
Description: Subject in group A will receive Ritonavir tablet 100mg twice daily.Subject in group B will receive Ritonavir tablet 100mg three times daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RTV
Description: Subject in group A will receive Ritonavir tablet 100mg twice daily.Subject in group B will receive Ritonavir tablet 100mg three times daily.
Study: NCT02777437

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XELOX or FOLFOX chemotherapy
Description: 4 cycles of XELOX or FOLFOX neoadjuvant chemotherapy before surgery
Study: NCT02470676

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pessary
Description: Two optional pessary sizes with the following dimensions: 65/17/35 or 70/17/35 and 200 mg daily progesterone vaginal suppositories (Utrogestan)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Progesterone
Description: 200 mg daily of vaginal progesterone suppositories (Utrogestan)
Study: NCT01367249

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bromfenac Ophthalmic Solution
Description: Sterile ophthalmic solution
Study: NCT00346905

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enteryx
Study: NCT02393742

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium nitrite

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT03201510

Intervention type: OTHER
Intervention: Observational
Description: HPTN 075 is an observational study in sub-Saharan MSM
Study: NCT01367249

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Sterile ophthalmic solution
Study: NCT02249104

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adapalene/benzoyl peroxide gel, 0.1%/2.5%
Description: Topical AV therapy
Study: NCT01342198

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pregabalin controlled release, 330 mg
Description: A single oral dose of 330 mg controlled release tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pregabalin controlled release, 330 mg
Description: A single oral dose of 330 mg controlled release tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: erythromycin
Description: A total of three doses of 500 mg erythromycin ethylsuccinate tablets administered six hours apart beginning approximately 1 hour prior to pregabalin CR
Study: NCT00702962

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vorinostat, Carboplatin, Etoposide
Description: Study originally a Phase I standard dose escalation of the study medication Vorinostat with sequential cohorts of 3-6 participants entered to 3 dose levels (200mg, 300mg, 400mg). Dose escalation stopped after participant 1 on dose level 2 due to recently published research identifying an appropriate dosing regimen. A set dose was then to be administered to all subsequent participants. This regimen (a cycle) consisted of Vorinostat on Day 1 through Day 4, Carboplatin AUC 6 on Day 3, and Etoposide 100 mg/m2 on Day 3 through Day 5. Treatment cycles were repeated every 21 days (3 weeks) for 4 cycles total.
Study: NCT01186705

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-2206
Description: Patients will receive MK-2206 orally in a once weekly dose of 200mg. There will be no dose escalation. Patients will be treated until disease progression or unacceptable side effects.
Study: NCT02545829

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HIP1302
Description: Tenofovir 292mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HIP1302
Description: Tenofovir 292mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HGP1406
Description: Tenofovir 300mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HGP1406
Description: Tenofovir 300mg
Study: NCT03730506

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intra oral scanner
Description: computer guided implant

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intra oral scanner
Description: computer guided implant

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Intra oral scanner
Description: computer guided implant
Study: NCT02249104

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cetaphil Acne Regimen
Description: Cleanse, Moisturize, and Protect
Study: NCT01779557

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Huaren Peritoneal Dialysate
Description: Huaren Peritoneal dialysate CAPD 3-5 times/d

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Baxter Peritoneal Dialysate
Description: Baxter Peritoneal dialysate CAPD 3-5 times/d
Study: NCT04839718

Intervention type: BEHAVIORAL
Intervention: ADAPT
Description: The Achieving Depression and Anxiety Patient Centered Treatment (ADAPT) Program is a novel collaborative psychiatric care model that is designed to unburden PCPs and psychiatrists, increase access to quality specialty mental healthcare for Kaiser Permanente members, and improve patient depression and anxiety treatment outcomes by utilizing technology-driven appointments. This program uses principles of collaborative care, including patient-centered care, population-based care, evidence-based care, measurement-based treatment to target, and accountable care.
Study: NCT04435938

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Body Radiotherapy (SBRT)
Description: 45 Gy in 5 fractions delivered once every 3-4 days
Study: NCT00733278

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Copper IUD ( ParaGard Intrauterine Contraceptive Device)
Description: Intraoperative placement of copper IUD at time of C-section
Study: NCT02479074

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Montelukast (High FeNO group)
Description: Montelukast 10 mg film-coated tablet contains montelukast sodium equivalent to 10 mg montelukast patients to take (oral use) one tablet per day for 28 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisolon, Montelukast (High FeNO)
Description: Prednisolone 5 mg, patients to take 4 tablets per day for 14 days then take Montelukast 10 mg tablet per day for another 14 days.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Montelukast (Low FeNO group)
Description: Montelukast 10 mg film-coated tablet contains montelukast sodium equivalent to 10 mg montelukast patients to take one tablet per day for 28 days
Study: NCT04374539

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Plasma exchange
Description: Plasma exchanges with 5% human albumin and fresh frozen plasma in patients with quick \<50% or only with 5% albumin in patients with quick of 50% or more. We will exchange between 1.2 and 1.5 plasma volumes, that will vary according to sex, weight, height and hematocrit.~Polyclonal immunoglobulin will be administered at a dose of 100 mg / kg ev after each plasma exchange.~Standar Medical treatment Kaletra:~lopinavir/ritonavir: 2c/12h 7 days~* Hydroxychloroquine sulfate 400 mg/12h the first day followed by 200 mg /12h 4 days~* Azithromycin 500 mg first day, followed by 250 mg /d 4 days (oral or EV)~* Tocilizumab 400 mg (weight \<75Kgs) or 600 mg (weight ≥ 75 Kg)~* Methylprednisolone 250 mg EV three days and 30 mg/d another 3 days~* Anakinra 200mg/ 12h SBC first day, 200mg / 24h SBC two more days~* Clexane 40-60 mg/d

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standar medical treatmen
Description: Kaletra: lopinavir/ritonavir: 2c/12h 7 days~* Hydroxychloroquine sulfate 400 mg/12h the first day followed by 200 mg /12h 4 days~* Azithromycin 500 mg first day, followed by 250 mg /d 4 days (oral or EV)~* Tocilizumab 400 mg (weight \<75Kgs) or 600 mg (weight ≥ 75 Kg)~* Methylprednisolone 250 mg EV three days and 30 mg/d another 3 days~* Anakinra 200mg/ 12h SBC first day, 200mg / 24h SBC two more days~* Clexane 40-60 mg/d
Study: NCT01132820

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cediranib Maleate
Description: Given PO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study: NCT04489953

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Viral Load
Description: For the Clinical and Immunologic criteria, viral load was done retrospectively on stored plasma samples. Whereas for the Clinical, Immunologic and Virologic criteria, viral load was done in real-time

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Viral Load
Description: For the Clinical and Immunologic criteria, viral load was done retrospectively on stored plasma samples. Whereas for the Clinical, Immunologic and Virologic criteria, viral load was done in real-time
Study: NCT02687035

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SAPIEN S3 valve
Description: Transcatheter aortic valve replacement
Study: NCT00967902

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: coronary stenting
Description: Balloon dilatation of obstructive coronary artery disease with deployment of a metallic stent to scaffold the dilated lesion; stent incorporating sustained release of anti-proliferative agent to control neointimal proliferation and reocclusion; test device incorporates affinity surface for circulating EPCs

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: coronary stenting
Description: Balloon dilatation of obstructive coronary artery disease with deployment of a metallic stent to scaffold the dilated lesion; stent incorporating sustained release of anti-proliferative agent to control neointimal proliferation and reocclusion; test device incorporates affinity surface for circulating EPCs
Study: NCT03330145

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Scales, questionnaires and inventory
Description: Children will complete scales, questionnaires and inventory at 3 months post-loss and only 2 scales at 6 and 12 month post-loss

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Scales, questionnaires and inventory
Description: Children will complete scales, questionnaires and inventory at 3 months post-loss and only 2 scales at 6 and 12 month post-loss
Study: NCT04185129

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Foster
Description: a randomized study for comparison asthma patients using Foster or Relvar. The primary end point is lung function improvement evaluation

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Foster
Description: a randomized study for comparison asthma patients using Foster or Relvar. The primary end point is lung function improvement evaluation
Study: NCT00245180

Intervention type: BEHAVIORAL
Group type: NO_INTERVENTION
Intervention: Diet
Study: NCT03574974

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Experimental Feedback
Description: Feedback is presented in the form of a line graph that is updated every 2 seconds throughout the scan to indicate activity in the target area. A red diamond will indicate periods of symptom provocation, during which participants are exposed to symptom-provoking auditory stimuli in the form of personalized trauma scripts and sound clips. A blue arrow will indicate periods of down-regulation, where participants will try to bring the feedback line down as much as possible (by trying to decrease their fear/anxiety). The investigators believe that this feedback may help participants learn to control their PTSD symptoms.~Participants will attend a total of 18 feedback scans over the course of 3 sessions.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Control Feedback
Description: Feedback is presented in the form of a line graph that is updated every 2 seconds throughout the scan to indicate activity in the target area. A red diamond will indicate periods of symptom provocation, during which participants are exposed to symptom-provoking auditory stimuli in the form of personalized trauma scripts and sound clips. A blue arrow will indicate periods of down-regulation, where participants will try to bring the feedback line down as much as possible (by trying to decrease their fear/anxiety). The investigators do not believe this feedback can help participants' PTSD symptoms.~Participants will attend a total of 18 feedback scans over the course of 3 sessions.
Study: NCT03692637

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: anti-Mesothelin Car NK Cells
Description: anti-Mesothelin Car NK Cells injection
Study: NCT01939730

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: 375 mg/m\^2 by vein once a week for 4 weeks on Days 1, 8, 15, 22.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GM-CSF
Description: 250 mcg subcutaneously 3 times a week for 8 weeks.
Study: NCT02440893

Intervention type: DIAGNOSTIC_TEST
Intervention: Corus CAD (ASGES)
Study: NCT01290302

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Luitpold Azacitidine
Description: Subcutaneous (SC) at a dose of 75 mg/m2 per day on days 1 and 2 of a treatment cycle

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vidaza®
Description: Subcutaneous (SC) at a dose of 75 mg/m2 per day on days 1 and 2 of a treatment cycle
Study: NCT01503983

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: Trastuzumab: 8 mg/kg day 1 followed by 6 mg/kg every 3 weeks (i.v.)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Capecitabine: 1000 mg/m2/12h/days 1 - 14 every 3 weeks (v.o.)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Oxaliplatin: 130 mg/m2 in 2 h, day 1 / (i.v.) /every 3 weeks
Study: NCT04020419

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PediaBerry
Description: PediaBerry or placebo will be mixed with a cream vehicle for topical administration or with water for oral administration

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: PediaBerry
Description: PediaBerry or placebo will be mixed with a cream vehicle for topical administration or with water for oral administration
Study: NCT02717728

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Drug group Fascia iliaca nerve block
Description: Device: Fascia Iliaca Catheter. Placement: Site prepared using aseptic technique.~Device: Portable ultrasound: Localization of target site. Aseptic preparation of probe with sterile sheath. 18g x 10mm echogenic enhanced needle, 20G catheter inserted 3 cm beyond needle tip.~Drug: Local anesthetic bolus: Ropivacaine 0.2% 0.5 ml/kg total in divided doses Device: Dressing Drug: Infusion of Ropivacaine 0.1%, rate: 0.3 ml/kg/hr; to start within the first hour after the block is placed. Infusion will be maintained for 24hs.

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Control group sham nerve block
Description: Device: Fascia Iliaca Catheter placement: Site prepared using aseptic technique.~Device: portable ultrasound: Localization of target site. Aseptic preparation of probe with sterile sheath.~Device: Dressing~Drug: Infusion of Ropivacaine 0.1%, rate: 0.3 ml/kg/hr; to start within the first hour after the block is placed. Infusion will be maintained for 24hs.